The artificial insemination industry in the US focuses on helping individuals and couples achieve pregnancy through various assisted reproductive technologies. Companies in this sector include fertility clinics, biotech firms, and medical device manufacturers that offer services ranging from sperm and egg donation to advanced genetic testing. With advancements in science, the industry is evolving towards more personalized treatments, celebrating inclusivity and addressing fertility challenges from diverse backgrounds. Moreover, public interest in reproductive health solutions continues to rise, creating robust opportunities for innovation and investment, ultimately shaping the future of family planning in America.

This list highlights 14 notable investors in the artificial insemination space, representing a mix of corporate and venture capital investors. Companies are spread across key locations, including New York, San Francisco, and Connecticut. Most firms were founded between 1976 and 2023, each has contributed significantly to the industry with deal counts ranging from single-digit acquisitions to over 170 in 2024, signaling a competitive investment environment.

Top 14 Artificial Insemination Investors in the US

1. Y Combinator

• Website: ycombinator.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2005
• Headcount: 51-200
• Number of deals in 2024: 802
• LinkedIn: y-combinator

Y Combinator is a prominent startup accelerator and venture capital firm based in San Francisco, California, founded in 2005. It provides funding and mentorship to early-stage technology companies through a structured program that helps entrepreneurs launch and grow their businesses. Y Combinator has successfully launched over 4,000 startups, making it a key player in the technology startup ecosystem. Among its notable investments, Y Combinator has backed companies in the artificial insemination and fertility space, including Legacy, which raised a total of $4.5 million in seed and pre-seed rounds in 2019, and Carrot Fertility, which raised $120,000 in a seed round in 2017. These investments highlight Y Combinator's engagement with the reproductive health sector, showcasing their commitment to supporting innovations in artificial insemination and fertility solutions.

2. Deep Tech Fund (an Alumni Ventures Fund)

• Website: av.vc
• Type: Venture Capital
• Headquarters: Manchester, New Hampshire, United States (USA)
• Founded year: 2023
• Headcount: 51-200
• Number of deals in 2024: 258
• LinkedIn: deep-tech-fund-av-focused-fund

Deep Tech Fund (an Alumni Ventures Fund) is a venture capital firm based in Manchester, New Hampshire, founded in 2023. It provides accredited investors and institutions with access to professionally-managed, diversified venture portfolios, leveraging a network of over 10,000 investors to connect them with high-quality investment opportunities in the startup ecosystem. The fund has been active in the fertility and reproductive health sector, with notable investments including Kindbody, which raised $15 million in Series A funding in April 2019, and Legacy, which raised $25 million in Series B funding in May 2023, as well as a $1 million pre-seed round in June 2019. These transactions highlight the fund's commitment to supporting innovative solutions in the artificial insemination and fertility treatment space.

3. CooperSurgical

• Website: coopersurgical.com
• Type: Corporate
• Headquarters: Trumbull, Connecticut, United States (USA)
• Founded year: 1990
• Headcount: 1001-5000
• Number of deals in 2024: 3
• LinkedIn: coopersurgical

CooperSurgical is a corporate investor based in Trumbull, Connecticut, specializing in women's health and fertility solutions. Founded in 1990, the company has established itself as a key player in the medical device manufacturing sector, focusing on innovative products and services that improve healthcare outcomes for women. In recent years, CooperSurgical has made several strategic acquisitions to bolster its position in the fertility market. Notably, they acquired Generate Life Sciences for $1.6 billion, which is expected to enhance their fertility solutions. Additionally, they have acquired ZyMōt Fertility, a company focused on assisted reproductive technology, and Reprogenetics, a leading genetics laboratory specializing in preimplantation genetic screening. These acquisitions reflect CooperSurgical's commitment to expanding its portfolio in the artificial insemination and reproductive health space, making them a significant investor in this field.

4. Sosv

• Website: sosv.com
• Type: Venture Capital
• Headquarters: United States (USA)
• Founded year: 1995
• Headcount: 51-200
• Number of deals in 2024: 170
• LinkedIn: sosv

Sosv is a venture capital firm founded in 1995, based in the United States, that specializes in funding and supporting deep tech startups through its development programs. With a focus on health and climate technology, Sosv provides venture capital investment and resources to help startups grow and succeed. Among its notable transactions, Sosv invested in Ivy Natal, which raised $250,000 in a seed round in April 2020, directly linking the firm to the artificial insemination and reproductive health sector. Other investments include Mojo and Bonzun, which, while not directly related to artificial insemination, indicate Sosv's broader commitment to health technology. This diverse portfolio showcases Sosv's capability to support innovative companies in various health-related fields.

5. Gaingels

• Website: gaingels.com
• Type: Venture Capital
• Headquarters: Burlington, Vermont, United States (USA)
• Founded year: 2015
• Headcount: 11-50
• Number of deals in 2024: 60
• LinkedIn: gaingels

Gaingels is a venture capital firm founded in 2015, based in Burlington, Vermont, dedicated to investing in companies with diverse leadership. The firm focuses on fostering diversity and inclusion in the innovation economy by providing capital and support to startups led by underrepresented groups. Gaingels has been involved in several relevant transactions in the artificial insemination and fertility sector, including Gameto, a biotech company that raised $17 million to develop partnerships with fertility clinics, and Cofertility, which raised $7.25 million in Series A funding. These investments highlight Gaingels' commitment to supporting innovative solutions in reproductive health, alongside their broader mission of enhancing board diversity and inclusion.

6. Kkr

• Website: kkr.com
• Type: Private Equity
• Headquarters: New York, New York, United States (USA)
• Founded year: 1976
• Headcount: 1001-5000
• Number of deals in 2024: 74
• LinkedIn: kkr

KKR & Co. Inc. is a prominent investment firm based in New York, specializing in private equity, credit, infrastructure, and real estate. Founded in 1976, KKR has established itself as a leader in asset management, providing solutions to institutional investors and individual clients. In recent years, KKR has made notable investments in the artificial insemination industry, acquiring IVI RMA GLOBAL on March 29, 2022, and IVI on January 12, 2023, both of which are key players in reproductive health. Additionally, KKR acquired GeneraLife IVF for approximately $459 million on November 10, 2021. These transactions highlight KKR's commitment to expanding its portfolio in the fertility and reproductive health sector, making it a significant investor in the artificial insemination space.

7. Founders Fund

• Website: foundersfund.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2005
• Headcount: 11-50
• Number of deals in 2024: 44
• LinkedIn: the-founders-fund

Founders Fund is a venture capital firm based in San Francisco, California, founded in 2005. The firm specializes in investing in innovative technology companies across various sectors, including aerospace and software development. They provide funding and strategic support to startups, helping them grow and scale their operations. Among their notable investments are companies like SpaceX and Palantir, showcasing their focus on high-impact ventures. In the context of reproductive health, Founders Fund has invested in Carrot Fertility, a startup that raised $3.6 million in seed funding to provide fertility benefits and services. Additionally, they participated in multiple funding rounds for Contraline, which raised over $10 million to support the development of a male contraceptive hydrogel implant, indicating their engagement in the fertility and reproductive health industry.

8. 500 Global

• Website: 500.co
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2010
• Headcount: 201-500
• Number of deals in 2024: 98
• LinkedIn: 500-startups

500 Global is a venture capital firm and startup accelerator based in San Francisco, California, founded in 2010. The firm specializes in investing in early-stage technology companies, providing funding, mentorship, and resources to help founders scale their businesses. In 2024, 500 Global has made 98 investments, showcasing its active role in the venture capital landscape. Notably, 500 Global has participated in transactions relevant to the artificial insemination context, such as its investment in Plenna, a Mexican femtech company that raised $4.4 million to expand its services related to maternity. This involvement highlights 500 Global's interest in women's health and reproductive technologies, aligning with the goals of companies in the artificial insemination industry.

9. What If Ventures

• Website: whatif.vc
• Type: Venture Capital
• Headquarters: Frisco, Texas, United States (USA)
• Founded year: 2020
• Headcount: 1-10
• Number of deals in 2024: 14
• LinkedIn: what-if-ventures

What If Ventures is a venture capital firm based in Frisco, Texas, founded in 2020. The firm focuses on funding and supporting startups primarily in the mental health and digital health sectors. They provide an accelerator program, funding opportunities, and resources to help these companies develop innovative solutions to address mental health challenges. In addition to their core focus, What If Ventures has made notable investments in the fertility and reproductive care space, particularly with Kindbody, which has raised significant funding in recent years. Kindbody, a hybrid fertility and reproductive care company, has successfully secured multiple rounds of funding, including a Series C round in June 2021 for $62 million, and additional rounds in 2022 and 2023, totaling over $25 million. This involvement highlights What If Ventures' potential interest in the artificial insemination sector, as Kindbody's services are directly related to fertility and reproductive health.

10. Lux Capital

• Website: luxcapital.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 47
• LinkedIn: lux-capital

Lux Capital is a venture capital firm based in New York, founded in 2000, that specializes in investing in science and technology companies. They provide venture capital investment and advisory services to startups across various innovative sectors. Notably, Lux Capital has invested in several fertility-focused startups, including Alife Health, which raised $22 million in Series A funding to develop AI tools for fertility assistance, and Gameto, which raised $33 million in Series B funding. Their investment in Fertilidad Integral also highlights their commitment to the fertility sector, as the company raised $3.5 million in a seed round. These transactions demonstrate Lux Capital's active role in supporting advancements in the artificial insemination and fertility industry.

11. New Enterprise Associates (NEA)

• Website: nea.com
• Type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Founded year: 1977
• Headcount: 51-200
• Number of deals in 2024: 57
• LinkedIn: new-enterprise-associates

New Enterprise Associates (NEA) is a prominent venture capital firm based in Menlo Park, California, founded in 1977. NEA specializes in investment management and advisory services for startups, particularly in the technology and healthcare sectors. The firm partners with entrepreneurs to provide funding and strategic guidance, emphasizing long-term relationships with founders. Among their notable transactions, NEA invested in ObsEva, a Swiss biopharmaceutical company that focuses on women's reproductive health, raising significant funds in both Series B and Post-IPO equity rounds. This involvement highlights NEA's engagement in sectors that may intersect with artificial insemination, although their broader investment strategy spans various industries beyond this niche.

12. GV (Google Ventures)

• Website: gv.com
• Type: Venture Capital
• Headquarters: San Francisco Bay Area, California, United States (USA)
• Founded year: 2009
• Headcount: 51-200
• Number of deals in 2024: 74
• LinkedIn: gv

GV (Google Ventures) is a venture capital firm founded in 2009, based in the San Francisco Bay Area, California. With over $10 billion in assets under management, GV focuses on funding and supporting innovative technology startups across various sectors, including life sciences and artificial intelligence. Notably, GV has invested in Kindbody, a New York-based fertility and wellness startup, participating in multiple funding rounds including Series A, B, and C, with total investments amounting to over $100 million. Additionally, GV led a $14 million Series A funding round for Granata Bio, a company dedicated to developing fertility biopharma solutions. These transactions highlight GV's commitment to advancing the artificial insemination and fertility industry.

13. OrbiMed

• Website: orbimed.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1989
• Headcount: 51-200
• Number of deals in 2024: 52
• LinkedIn: orbimed-advisors

OrbiMed is a prominent investment firm based in New York, specializing in healthcare investments since its founding in 1989. With approximately $17 billion in assets under management, OrbiMed focuses on driving innovation in the healthcare sector through strategic investments in biopharmaceuticals, medical devices, and healthcare services. Among their notable transactions, OrbiMed has invested in Jinxin Fertility, which raised $150 million in a Series F round, and Carrot Fertility, which secured $75 million in a Series C round. These investments highlight OrbiMed's engagement in the fertility and artificial insemination industry, showcasing their role in supporting companies that provide reproductive health solutions. Additionally, their involvement in other healthcare-related investments further solidifies their position as a key player in the healthcare investment landscape.

14. Portfolia

• Website: portfolia.co
• Type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Founded year: 2013
• Headcount: 51-200
• LinkedIn: portfolia

Portfolia is a venture capital firm based in Palo Alto, California, founded in 2013. The firm focuses on investing in innovative companies that address women's health and social issues, providing accredited investors, particularly women, with opportunities to engage in venture capital funding. Portfolia has been involved in several notable transactions in the fertility and reproductive health space. For instance, they participated in the Series A funding for Future Family, a fertility care company that raised $10 million to expand its subscription service to fertility clinics. They also invested in Proov, which raised $9.7 million for its at-home ovulation testing platform, aimed at addressing ovulation and uterus readiness issues. Additionally, Portfolia's investment in Inherent Biosciences, which is developing a diagnostic product called SpermQT, highlights their commitment to advancing technologies related to sperm analysis and fertility diagnostics. These transactions underscore Portfolia's active role in the artificial insemination and broader fertility industry.

Artificial Insemination Insights: Key Investors in the US

Investor	Headquarter	Size	Founded	Deals 2024
Y Combinator	San Francisco, California, United States (USA)	51-200	2005	802
Deep Tech Fund (an Alumni Ventures Fund)	Manchester, New Hampshire, United States (USA)	51-200	2023	258
CooperSurgical	Trumbull, Connecticut, United States (USA)	1001-5000	1990	3
Sosv	United States (USA)	51-200	1995	170
Gaingels	Burlington, Vermont, United States (USA)	11-50	2015	60
Kkr	New York, New York, United States (USA)	1001-5000	1976	74
Founders Fund	San Francisco, California, United States (USA)	11-50	2005	44
500 Global	San Francisco, California, United States (USA)	201-500	2010	98
What If Ventures	Frisco, Texas, United States (USA)	1-10	2020	14
Lux Capital	New York, New York, United States (USA)	11-50	2000	47
New Enterprise Associates (NEA)	Menlo Park, California, United States (USA)	51-200	1977	57
GV (Google Ventures)	San Francisco Bay Area, California, United States (USA)	51-200	2009	74
OrbiMed	New York, New York, United States (USA)	51-200	1989	52
Portfolia	Palo Alto, California, United States (USA)	51-200	2013	0

Want to find more investors focusing on the artificial insemination industry?

If you want to find more investors that are active in the artificial inseminationindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and their sizes.
• Portfolio: Companies they've invested in.
• Contact data: Key dealmakers, including their emails and phonenumbers.
• ...and much more!